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Abstract 
We developed, synthesized, and tested a multifunctional nanostructured lipid nanocarrier-
based system (NLCS) for efficient delivery of an anticancer drug and siRNA directly into the 
lungs  by  inhalation.  The  system  contains:  (1)  nanostructured  lipid  carriers  (NLC);  (2) 
anticancer  drug  (doxorubicin  or  paclitaxel);  (3)  siRNA  targeted  to  MRP1  mRNA  as  a 
suppressor of pump drug resistance; (4) siRNA targeted to BCL2 mRNA as a suppressor of 
nonpump cellular resistance and (5) a modified synthetic analog of luteinizing hormone-
releasing  hormone  (LHRH)  as  a  targeting  moiety  specific  to  the  receptors  that  are 
overexpressed in the plasma membrane of lung cancer cells. The NLCS was tested in vitro 
using human lung cancer cells and in vivo utilizing mouse orthotopic model of human lung 
cancer.  After  inhalation,  the  proposed  NLCS  effectively  delivered  its  payload  into  lung 
cancer  cells  leaving  healthy  lung  tissues  intact  and  also  significantly  decreasing  the 
exposure of healthy organs when compared with intravenous injection. The NLCS showed 
enhanced antitumor activity when compared with intravenous treatment. The data obtained 
demonstrated  high  efficiency  of  proposed  NLCS  for  tumor-targeted  local  delivery  by 
inhalation of anticancer drugs and mixture of siRNAs specifically to lung cancer cells and, 
as a result, efficient suppression of tumor growth and prevention of adverse side effects on 
healthy organs. 
 
Keywords:  Nanostructured  lipid  carrier;  orthotopic  lung  cancer  model;  inhalation; 
luteinizing hormone-releasing hormone (LHRH); imaging; drug resistance. ACCEPTED MANUSCRIPT
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Introduction 
Lung cancer is the leading cancer killer in both men and women. Despite advantages in 
surgical  lung  cancer  treatment,  chemotherapy  continues  to  play  an  important  role  as 
primary  and  supportive  care  in  treating  lung  cancer  [1-5].  Conventional  intravenous 
chemotherapy  usually  employs  high  doses  of  toxic  drugs  which  often  induce  severe 
adverse side effects on healthy organs. Alternatively, oral delivery of anticancer drugs for 
lung cancer treatment is usually compromised by poor bioavailability of the drug for lung 
cancer  cells  and  its  degradation  during  the  first-pass  metabolism.  Therefore,  an  ideal 
therapy  of  lung  cancer  would  provide  for  the  administration  of  high  doses  of  drugs 
specifically to the lung tumor tissues via the inhalation for the maximum treatment efficiency 
and low adverse side effects. The most important advantages of the pulmonary route for 
drug  administration  are  a  large  absorptive  surface  of  lungs  for  aerosol  deposition, 
avoidance of the first-pass metabolic degradation, limited penetration of inhaled drug(s) into 
the systemic circulation and, as a result, fewer adverse side effects on healthy organs. 
Several  formulations  of  traditional  anticancer  drugs  were  already  adopted  for  the  local 
inhalation delivery [6-9]. However, despite the advantages, the efficient inhalation delivery 
currently  is  possible  for  only  a  limited  number  of  drugs.  In  addition,  the  efficacy  of 
chemotherapy  is  also  limited  by  the  rapid  development  of  tumor  resistance.  The 
PHFKDQLVPV RI WKLV UHVLVWDQFH DUH FRPPRQ WR PRVW FDQFHUV DQG LQFOXGH ³SXPS´ DQG
³QRQSXPS´ GUXJ UHVLVWDQFH [10,  11].  The  pump  resistance  is  caused  by  membrane 
transporters that pump out drugs from cells, decreasing the efficacy of the treatment [12-
16]. The main mechanism of nonpump resistance is an activation of cellular antiapoptotic 
defense [10, 11, 17-20]. Recently, we showed that siRNA can be effectively used for the 
suppression of proteins, responsible for 
both  pump  and  nonpump  drug 
resistance  in  different  cancer  cells 
including lung cancer cells [17, 20-22]. 
Consequently,  the  development  of 
nanomedicine platform capable of tumor 
targeted  combinatorial  delivery  of 
anticancer  drugs  and  siRNA  as 
suppressors  of  pump  and  nonpump 
cellular  resistance  via  pulmonary  route 
is  highly  desirable.  Recently,  several 
different  nanocarriers  have  been 
developed  for  inhalation  delivery  of 
different  drugs  and  nucleic  acids  [22-
24]. However, used carriers, especially 
liposomes,  have  some  drawbacks,  in 
particular  for  the  efficient  delivery  of 
siRNA.  In  order  to  circumvent  these 
salient  weak  points,  we  designed 
Nanostructured Lipid Carriers (NLC) for 
inhalation  delivery  of  anticancer  drugs 
LHRH
DSPE-PEG
DOTAP
Drug
siRNA
 
Figure  1.  A  schematic  representation  of 
Nanostructured  Lipid  Carrier  (NLC)-based  drug 
delivery system for pulmonary co-delivery  of an 
anticancer drug,  siRNA and targeting peptide. 
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and siRNA. NLC are a new generation of lipid nanoparticles, which are developed through 
the combination of advantages from different nanocarriers including liposomes  [25]. The 
proposed  NLC  based  system  (NLCS)  was  designed  to  fulfill  the  following  tasks:  (1)  to 
provide  local  inhalation  lung  delivery  of  active  components;  (2)  to  suppress  pump  and 
nonpump resistance; (3) to offer targeted drug delivery specifically to the cancer cells and 
(4) to limit adverse side effects on healthy lung tissues and other organs.  Consequently, 
we  designed  a  highly  efficient  NLCS  for  inhalation  therapy  which  contains  five  main 
components: (1) NLC as the carriers; (2) anticancer drug; (3) siRNA targeted to MRP1 
mRNA as a suppressor of pump drug resistance; (4) siRNA targeted to BCL2 mRNA as a 
suppressor of nonpump cellular resistance and (5) a modified synthetic analog of luteinizing 
hormone-releasing hormone (LHRH) as a targeting moiety specific to the receptors that are 
overexpressed in the plasma membrane of lung cancer cells (Fig 1). 
Materials and methods 
Materials  
Precirol ATO 5 was  generously provided by Gattefossé USA (Paramus, NJ).  Soybean 
phosphatidylcholine  (SPC),  Doxorubicin  (DOX),  Paclitaxel  (TAX),  Triethylamine  (TEA), 
Squalene, Tween-80, Mannitol were purchased from Sigma Aldrich (St. Louis, MO). DSPE-
PEG-NH2  (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene 
glycol)-2000]  (ammonium  salt)),  DSPE-PEG-COOH  (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene  glycol)-2000]  (ammonium  salt))  and 
DOTAP  (1,2-dioleoyl-3-trimethylammonium-propane  (chloride  salt))  were  obtained  from 
Avanti Polar Lipids (Alabaster, AL). Cy5.5 NHS ester was purchased from GH Healthcare 
Life  Sciences  (Piscataway,  NJ).    A  modified  synthetic  analog  of  Luteinizing  Hormone-
Releasing Hormone (LHRH) decapeptide (Gln-His-Trp-Ser-Tyr-DLys(D-Cys)-Leu-Arg-Pro) 
was synthesized according to our design by American Peptide Company, Inc. (Sunnyvale, 
CA). The sequence of native LHRH peptide, which is similar in human, mouse, and rat, was 
modified to provide a reactive amino group only on the side chain of a lysine residue, which 
replaced Gly at the position 6 to yield the superactive, degradation-resistant-Lys-6-des-Gly-
10-Pro-9-ethylamide LHRH analog [19, 26]. The synthesized sequence of LHRH peptide is 
highly efficient for targeting of drug delivery systems specifically to the cancer tumors [18-
20, 27, 28] and Cys residue do not influence the recognition process. The sequences of 
siRNA  targeted  to  BCL2  (sense  strand:  5ƍ-GUG-AAG-UCA-ACA-UGC-CUG-CdTdT-3ƍ
antisense strand: 5ƍ-GCA-GGC-AUG-UUG-ACU-UCA-CdTdT-¶DQG053sense strand: 
5ƍ-GGC-UAC-AUU-CAG-AUG-ACA-CdTdT-3ƍ DQWLVHQVH VWUDQG 5ƍ-GUG-UCA-UCU-GAA-
UGU-AGC-CdTdT-¶P51$ZHUHFXVWRPV\QWKHVL]HGDFFRUGLQJWRRXUGHVLJQE\$PELRQ
(Austin, TX).  
Cell line 
A549 human lung adenocarcinoma cells were obtained from the ATTC (Manassas, VA); 
A549  cells  transfected  with  luciferase  were  purchased  from  Xenogen  Bioscience, 
(Cranbury,  NJ).  Cells  were  cultured  in  RPMI  1640  medium  (Sigma,  St.  Louis,  MO) 
supplemented  with  20%  fetal  bovine  serum  (Fisher  Chemicals,  Fairlawn,  NJ)  and  1.2 
mL/100 mL penicillin±streptomycin (Sigma, St. Louis, MO). Cells were grown at 37 °C in a 
humidified atmosphere of 5% CO2 (v/v) in air. All experiments were performed on cells in 
the exponential growth phase. ACCEPTED MANUSCRIPT
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Preparation of NLC 
Drug loaded NLC were prepared by a modified melted ultrasonic dispersion method [29, 
30]. Prior to the NLC preparation, the doxorubicin hydrochlorate (DOX·HCl) was stirred with 
twice  the  molar  amount  of  TEA  in  DMSO  for  12  h  to  obtain  lipophilic  DOX  base  [31]. 
Typically, DOX base or TAX dissolved in 1 mL of DMSO was added to the hot lipid phase 
consisted of 100 mg Precirol ATO 5 (solid lipid), 100 mg Squalene (liquid lipid) and 5 mg 
SPC (lipophilic emulsifier). Aqueous phase was prepared by dissolving 250 mg Tween-80 
(surfactant) and 25 mg DOTAP (cationic lipid) in 10 mL of DI water. In order to prepare 
PEG coated NLC, 10 mg DSPE-PEG-COOH was additionally added to the aqueous phase. 
Both phases were maintained for 15 min at 80 °C in the oil bath under magnetic stirring. 
Then the hot lipid phase was added slowly to the aqueous solution and dispersed using a 
high-speed homogenizer (PRO Scientific Inc. Oxford, CT) for 5 min at 12,000 RPM. The 
crude emulsion was additionally treated by a probe type ultrasonicator (Fisher Scientific 
Model 120 Sonic Dismembrator) for 5 min at 3 W. Then, the hot emulsion was cooled at 4 
°C on an ice bath, maintaining the mechanical stirring for 60 min. After preparation, the 
NLC were purified by dialysis (MWC 10,000) and subjected to lyophilization. Mannitol (5%) 
was added into NLC suspension as cryoprotector. The obtained powder was stored at 4 °C 
until further use. 
Preparation of fluorescence labeled and LHRH targeted NLC 
Prior  preparation  of  targeted  NLC,  DSPE-PEG-NH2  and  DSPE-PEG-COOH  were 
conjugated with Cy5.5 and LHRH peptide, respectively, as previously described [27, 32]. 
LHRH targeted NLC (a), Cy5.5 labeled NLC  (b) or Cy5.5 labeled and LHRH targeted NLC 
(c) were prepared by adding (a) 10 mg of DSPE-PEG-LHRH,  (b) 10 mg of DSPE-PEG-
COOH : DSPE-PEG-Cy5.5 (10:1) and (c) 10 mg of DSPE-PEG-LHRH : DSPE-PEG-Cy5.5 
(10:1) to the hot lipid phase instead of DSPE-PEG-COOH, respectively.  
Preparation of siRNA-NLC complexes 
The siRNA complexes were prepared at w/w (weight NLC/weight siRNA) ratio of 117:1 in 
water by adding stock solution of NLC into a prepared siRNA solution (BCL2 siRNA: MRP1 
siRNA = 1:1). The weight ratio (siRNA/NLC) was determined from Ethidium Bromide (EtBr) 
dye displacement assay. The final concentrations of siRNAs (BCL2:MRP1 =1:1) and drug 
loaded NLC in the solution were 128.5  g/mL and 15 mg/mL, respectively. The samples 
were vortexed, and the solutions were then incubated at room temperature for 30 min to 
ensure  complex  formation.  It  should  be  stressed  that  lipid  composition  of  both  siRNA 
loaded and siRNA free NLC was the same in our study.   
Particle size, shape, zeta potential and cytotoxicity 
The particle size distribution and the zeta potential of the prepared NLC were measured by 
Malvern  ZetaSizer  NanoSeries  (Malvern  Instruments,  UK)  according  to  manufacturer 
instructions. All measurements were carried out at room temperature. Each parameter was 
measured five times, and average values and standard deviations were calculated. The 
shape  of  the  NLC  was  determined  by  Atomic  Force  Microscope  (AFM)  as  previously 
described [33]. In order to image the prepared NLC, 5  L of the solutions were deposited 
on freshly cleaved mica. After 5 minutes of incubation, the mica surface was rinsed with 3 
drops of DI water for 4 times and dried under a flow of dry nitrogen. The samples of the ACCEPTED MANUSCRIPT
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condensates were imaged with a tapping mode atomic force microscope (Nanoscope III A, 
Digital Instruments, Santa Barbara, CA). Cytotoxicity of nanoperticles was analyzed using a 
modified  3-(4,  5-dimethylthiazol-2-yl)-2,  5-diphenyltetrazolium  bromide)  (MTT)  assay  as 
previously described [10, 11, 17]. 
Evaluation of NLC condensation ability by ethidium bromide dye displacement assay 
Fluorescence  titration  of  siRNA/EtBr  with  the  complexation  agents  were  performed  as 
previously described [21]. The complexes were prepared by the intercalation of siRNA with 
(W%UDWUDWLRVL51$EDVHSDLUVWR(W%ULQZDWHUȝ/DOLTXRWVRIPJP/1/&ZHUH
VHTXHQWLDOO\DGGHGWRȝ0VROXWLRQRIVL51$LQȝ/ZDWHUFRQWDLQLQJ(W%U$Iter each 
addition, the mixture was stirred and the fluorescence of the solution was measured (590 
nm  emission;  490  nm  excitation).  Binding  NLC  caused  a  displacement  of  bound  EtBr, 
resulting in a decrease in the fluorescence emission intensity.  
Determination of siRNA binding to NLC by agarose gel retardation assay 
siRNA  binding  to  LHRH-Drug-NLC  was  evaluated  by  agarose  gel  retardation  assay  as 
previously described [21]. siRNA-NLC complexes were prepared at different  w/w ratios: 
1:10, 1:50, 1:100, 1:117. The samples were further diluted with water, electrophoresed in 4 
% agarose gel at 100 mV for 60 min in DPBS and stained with EtBr. The gels were digitally 
photographed and scanned using the Gel Documentation System 920 (Nucleo-Tech, San 
Mateo, CA). 
Orthotopic lung cancer model, imaging and treatment 
All animal experiments were carried out according to the approved protocol and institutional 
guidance. A mouse orthotopic model of human lung cancer previously developed in our 
laboratory [22, 23, 34] was used in the current study.  Briefly, athymic nu/nu mice (NCRNU-
M,  CrTac:NCr-Foxn1nu)  were  purchase  from  Taconic  Farms,  Inc  (Cranbury,  NJ).  A549 
human lung adenocarcinoma epithelial cells (5-8   10
6) transfected with luciferase were re-
suspended in 0.1 mL of RPMI medium containing 20% fetal bovine serum, mixed with 5 µl 
of EDTA and were administered to the mouse lungs through a catheter. The development 
of  tumor  growth  was  monitored  and  tumor  volume  was  calculated  by  different  imaging 
systems  in  live  animals.  All  imaging  procedures  were  performed  under  inhalation 
anesthesia with isoflurane at a concentration of 4% for induction of anesthesia and 1±2% 
for maintenance. Mice were placed in prone position with isoflurane supplied via a nose 
cone. After image data acquisition, the recovery time of the animals from anesthesia was 
usually less than five minutes. Optical imaging was performed using In-Vivo bioluminescent 
IVIS  (Xenogen,  Alameda,  CA)  and  MS  FX  PRO®  (Carestream  Molecular  Imaging, 
Woodbridge, CT) systems. In order to visualize cancer cells transfected with luciferase, 
luciferin was injected intraperitoneally in dose of 150 mg luciferin/kg of body weight 10 -15 
minutes before imaging.  The quantitative analysis of tumor size and volume using optical 
imaging system was described previously [34]. Magnetic Resonance Imaging (MRI) was 
SHUIRUPHGXVLQJD70ZKROHERG\VFDQQHU$VSHFW,PDJLQJ6KRKDP,VUDHO7
weighted images (repetition time 2607 ms, echo time 44 ms) were recorded in Fast Spin 
Echo sequence. At a spatial resolution of 312 micron, the tumors were coronal imaged in a 
single section through the lung using an image matrix of 256 × 256, a field of view of 80 
mm
2, and 4 excitation. Tumor volume was calculated using Vivoquant 1.21 software. The 
Computed  Tomography  (CT)  scan  was  done  with  Albira  high-resolution  PET/computed ACCEPTED MANUSCRIPT
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tomography  scanner  (Carestream  Molecular  Imaging,  Woodbridge,  CT).  The  scan 
parameters were set as follow: tube voltage 45 kVp, tube current 400 µA, FOV 70 x 70 mm, 
detector pixels 2400 x 2400. Total scan duration was about 12 minutes. Image data was 
reconstructed using the FBP algorithm. The resulting voxel size of the isotropic dataset was 
125 microns. CT datasets were visualized using the software packages PMOD 3.3 (PMOD 
Technologies)  and  Volview  3  (Kitware  Inc.,  Clifton  Park,  NY).  Ultrasound  imaging  was 
carried out using Vevo 2100 system (VisualSonics, Toronto, Canada).  Tumor size and 
volume was calculated in 2- and 3-dimensional images using manufacture software. Four-
six weeks after the instillation of tumor cells, when the tumor in lungs reached a volume of 
about 40 mm
3, mice were treated on days 0, 3, 7, 11, 14, 17, 21, and 24 using previously 
developed  regimen  and  nose-only  exposure  chamber  for  inhalation  of  small  laboratory 
animals [34, 35]. The following series of experiments were carried out: (1) Untreated mice 
(control); (2) mice treated by intravenous injection of TAX; mice treated by inhalation with: 
(3) LHRH-NLC; (4) LHRH-NLC-TAX; (5) LHRH-NLC-TAX-siRNAs (targeted to MRP1 and 
BCL2 mRNAs). The dose of TAX in all drug-containing formulations was 2.5 mg/kg for the 
single  administration.  This  dose  corresponds  to  the  maximum  tolerated  dose  (MTD)  of 
LHRH-SLN-TAX delivered by inhalation.  The MTD was estimated in separate experiments 
based on animal weight change after the instillation of increasing doses of drug formulation 
as  previously  described  [19,  34, 36]. The dose  of  siRNA  was  170  g/kg  for the  single 
administration. The dose of free non-bound TAX used for intravenous injection was also 2.5 
mg/kg.  Animal  weight  was  monitored  every  day  during  the  treatment  period.  After  the 
treatment, all mice were anesthetized with isoflurane and euthanized. The organs (lungs, 
heart, liver, kidney, spleen, and brain) were excised and used for further analysis. Changes 
in tumor volume were used as an overall marker for antitumor activity.    
Distribution of NLC in different organs, normal and tumorous lung tissues 
Organ distribution labeled by Cy5.5 NLC was studied as previously described [22, 23, 27, 
34].  Briefly, animals were anesthetized with isoflurane using the XGI-8 Gas Anesthesia 
System (Xenogen, Alameda, CA). Fluorescence of labeled with Cy5.5 NLC was visualized 
24 h after the i.v. injection or by inhalation using IVIS imaging system. Visible light and 
IOXRUHVFHQFHLPDJHVZHUHWDNHQDQGRYHUODLGXVLQJWKHPDQXIDFWXUHU¶VVRIWZDUHWRREWDLQ
composite images. The distribution of fluorescence in different organs (liver, kidney spleen, 
heart, brain and lungs) was analyzed using original software developed in our laboratory. 
After sacrificing animals, lungs were excised, washed in ice-cold saline and kept frozen. 
LHRH-targeted  Cy5.5-TAX-NLC-siRNA  accumulation  in  lung  tissues  (tumorous  and 
healthy) was visualized by fluorescence microscopy (Olympus America Inc., Melville, NY) 
on frozen 5 mm tissue sections as described [36].  
Accumulation  of  NLC  in  lung  tumor,  cellular  uptake  and  localization  of  drug  and 
siRNA 
Internalization of osmium-labeled NLC by lung cells was studied by electron transmission 
microscopy in lung tissue sections fixed prior to microscopy using standard techniques as 
previously described [16, 37, 38]. Briefly, lung tissXHVOLFHVZHUHIL[HGIRUKLQ7UXPS¶V
EM Fixative (combination of low concentration of both formaldehyde and glutaraldehyde in 
00LOORQLQJ¶V3KRVSKDWHEXIIHUS+3RVWIL[DWLRQZDVFDUULHGRXWLQ2VPLXP
Tetroxide in buffer for 1 h followed by dehydration in graded Ethanol series and embedded 
LQ6SXUU¶V/RZ9LVFRVLW\5HVLQ6HFWLRQVZHUHSUHSDUHGXVLQJDGLDPRQGNQLIHE\/.%-ACCEPTED MANUSCRIPT
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2088 Ultramicrotome (LKB-Produkter / Bromma, Sweden). Observation and micrographs 
were  made  with  a  JEM-100CXII  Electron  Microscope.  (Jeol  Ltd.,  Tokyo,  Japan). 
Fluorescent  dye-labeled  siRNA  was  synthesized  by  Ambion  according  to  our  design 
through the conjugation of FAM dye (green color) to the 5' siRNA antisense strand. Intrinsic 
fluorescent of DOX (red color) was employed for the detection of drug internalization into 
the cancer cells. Prior to the visualization, A549 cells were plated (10 000 cells/well) in 6-
well tissue culture plate and incubated with the studied formulation for 3 h. In addition, cell 
nuclei  were  stained  by  a  nuclear  dye  (4',  6-diamidino-2-phenylindole,  DAPI,  Sigma 
Chemical  Co.,  St.  Louis,  MO).  Cellular  internalization  of  LHRH-DOX-NLC-siRNA 
complexes were analyzed by a fluorescence microscope (Olympus America Inc., Melville, 
NY) as previously described [21, 39]. 
Suppression of targeted mRNA 
The  expression  of  BCL2  and  MRP1  mRNA  was  analyzed  by  quantitative  reverse 
transcription-polymerase chain reaction (RT-PCR). The following pair of primers were used: 
BCL2 í GGA TTG TGG CCT TCT TTG AG (sense), CCA AAC TGA GCA GAG TCT TC 
(antisense); MRP1í ATG TCA CGT GGA ATA CCA GC (sense), GAA GAC TGA ACT 
CCC TTC CT (antisense); ȕ-m (internal stanGDUGí$&&&&&$&7*$$$$$*$7*$
(sense), ATC TTC AAA CCT CCA TGA TG (antisense). The extraction of RMA and RT-
PCR were performed as previously described [11, 22].   
Statistical analysis.  
Data were analyzed using descriptive statistics, single-factor analysis of variance (ANOVA), 
and presented as mean values ± standard deviation (SD) from four to eight independent 
measurements. The comparison among 
groups  was  performed  by  the 
independent  VDPSOH VWXGHQW¶V t-test. 
The  difference  between  variants  was 
considered significant if P < 0.05. 
Results 
Preparation  of  drug  loaded,  tumor 
targeted NLC 
In  the  current  study,  drug-loaded, 
cationic  NLC  were  successfully 
prepared  using  DOX  or  TAX  as  the 
model chemotherapeutic agents. Due to 
intrinsic  fluorescence  of  DOX,  it  was 
primarily  selected  to  evaluate  uptake 
and  intracellular  localization  of 
anticancer  drugs  delivered  by  NLCS. 
On  the  other  hand,  TAX  was  used  to 
assess  anticancer  efficacy  of  the 
developed  NLCS.  To  facilitate  the 
entrapment  efficiency  of  positively 
charged  DOX  in  the  oil  phase,  DOX 
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Figure  2.  Characterization  of  LHRH-targeted 
paclitaxel  (TAX)-loaded  Nanostructured  Lipid 
Carriers  (LHRH-NLC-TAX-siRNA).  (A)  Size 
distribution of LHRH-NLC-TAX-siRNA measured 
by  dynamic  light  scattering  before  and  after 
nebulization. (B) Atomic Force Microscope image 
of LHRH-NLC-TAX-siRNA. ACCEPTED MANUSCRIPT
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base  was  prepared  by  mixing  DOX  hydrochloride  with  negatively  charged  TEA  as 
previously reported [31]. Using the centrifugation ultrafiltration method, it was demonstrated 
WKDWGUXJORDGLQJRIQDQRSDUWLFOHVZDVZZIRUERWK'2;EDVHDQG7$;ȝJRIGUXJ
SHUȝJRIOLSLG Dynamic light scattering and atomic force microscopy studies revealed 
that the drug loaded NLC were 110 ± 20 nm in diameter with polydispersity index of 0.4 
(Fig.  2A).  The  most  optimal  regimen  of  nebulization  was  previously  selected  in  our 
laboratory in order to avoid nanoparticle destruction and release of drug and siRNA [40]. 
The measurement of particle size distribution before and after nebulization showed that 
nebulization did not influence the stability of the nanoparticles and conjugated siRNA (Fig. 
2).  As  AFM  measurements  demonstrated  (Fig.2B),  spherical  nanoparticles  were  the 
predominant  products,  as  seen  on  mica  surfaces.    (Fig.  2A  and  B).  A  30-day  physical 
stability test of the drug-NLC at 4 ºC was also conducted and no statistical difference was 
found in the particle size over time. In order to enhance steric stability of NLCS and reduce 
its uptake by cells of reticuloendothelial system, the NLC surface was modified with PEG. 
Furthermore,  a  synthetic  analog  of  LHRH  peptide  was  conjugated  to  the  distal  end  of 
DSPEG-PEG-COOH  via  amide  bond  formation  as  a  ligand  to  corresponding  LHRH 
receptors that are overexpressed in the plasma membrane of many types of cancer cells 
[18, 19, 27, 28, 39, 41] to direct the NLCS specifically to the lung cancer cells and limit the 
adverse cytotoxic side effects of chemotherapy on healthy organs and non-cancerous lung 
tissues.  
Characterization of siRNA complexation efficiency of NLC 
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Figure  3.  Complexation  of  siRNA  with  NLC.  (A)  A  representative  agarose  gel 
electrophoresis image illustrating siRNA complexation efficiency by LHRH-NLC-TAX at the 
following w/w ratio (weight NLC/weight siRNA): (1) 0:1 (naked siRNA, control); (2) 10:1; (3) 
50:1; (4) 100:1; and (5) 117:1. Complexation of siRNA prevented staining of siRNA by 
ethidium  bromide  and  led  to  the  disappearance  of  the  siRNA  band.  Therefore,  the 
fluorescent intensity of the siRNA band on the gel (well 5) disappeared when siRNA was 
complexed with NLC at w/w ratio = 117:1. (B) siRNA complexation efficiency of LHRH-
NLC-TAX evaluated by the ethidium bromide dye displacement assay. The arrow on the 
curve highlights the w/w ratio corresponding to the apparent end of siRNA complexation 
with NLC. Means ± SD are shown.  ACCEPTED MANUSCRIPT
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The developed NLCS was aimed to suppress multidrug resistance in cancer cells by siRNA 
targeted to proteins responsible for cellular resistance. In most lung cancers, this resistance 
is usually  associated with  the  overexpression  of  (1) MRP1 protein  responsible for drug 
efflux from the cancer cells (pump resistance) and (2) BCL2 protein that is responsible for 
antiapoptotic cellular defense (non-pump resistance) [11, 17, 22, 34]. Consequently, we 
incorporated two types of siRNA targeted to MRP1 and BCL2 mRNA into the proposed 
NLCS  for  the  effective  suppression  of  cellular  resistance.  To  this  end,  we  made  NLC 
positively charged via the incorporation of DOTAP as cationic lipid into the nanoparticle 
structure.  Since,  efficiency  of  siRNA  condensation  depends  only  on  the  amount  of 
polycations and does not rely on siRNA sequence; the developed NLC could be used for 
simultaneous condensation of siRNA molecules targeted to both MRP1 and BCL2 genes. 
The efficiency of the prepared NLC to bind and form complexes with siRNA molecules via 
electrostatic interaction was determined by agarose gel retardation and ethidium bromide 
dye displacement assays (Fig. 3). We found that the complete condensation of siRNA was 
achieved  at  the  ratio  of  NLC  to  siRNA  (weight/weight)  around  117:1  leading  to  the 
disappearance  of  siRNA  band  on  the  agarose  gel  (Fig.  3A)  and  decrease  in  the 
fluorescence of ethidium bromide down to the background level (Fig. 3B). Consequently, 
this NLC/siRNA ratio was used to form NLC-siRNA complexes that were further used in the 
following investigations. 
Zeta potential and cytotoxicity 
The  measurement  of  cellular  viability  showed  that  positively  charged  NLC  (+  60.3  mV) 
demonstrated a signs of cytotoxicity (Fig. 4A, bar 2). The viability of cells incubated with 
NLC decreased by approximately 20% (P < 0.05 when compared with control). Caging of 
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Figure 4. Viability of multidrug-resistant H69AR human lung cancer cells incubated for 48 
hours with the indicated formulations. A, cytotoxicity of formulations that do not contain 
DTAX; B, cytotoxicity of formulations that contain TAX. Means ± SD are shown. *P < 0.05 
when compared with control. ACCEPTED MANUSCRIPT
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nanoparticles with PEG eliminated this effect (Fig. 4A, bar 3). Zeta potential of NLC-siRNA 
complexes decreased to +45.5 mV while caging with PEG almost completely eliminated the 
charge of nanoparticles. In contrast, nanoparticles containing the drug were highly toxic. 
The  data  obtained  show  that  incorporation  of  TAX  into  tumor-targeted  nanoparticles 
increased its toxicity to cancer cells overexpressed LHRH receptors in 7.5 times (Fig. 4B, 
compare bars 2 and 1). Simultaneous suppression of BCL2 and MRP1 proteins by siRNA 
led to the further enhancement in cytotoxicity of an entire complex. In fact, cytotoxicity of 
LHRH-NLC-TAX-siRNAs (MRP1 and BCL2) complexes was 120 and 16 times higher when 
compared with free drug and LHRH-NLC-TAX, respectively (Fig. 4B, bar 3). 
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Figure 5. Accumulation of LHRH-NLC in the lung tissues after the inhalation delivery (A) 
and  intracellular  localization  of  the  drug  and  siRNA  released  from  NLC  (B-E). 
Representative  transmission  electron  microscopy  image  of  LHRH-targeted  NLC  labeled 
with  osmium  tetroxide  in  lung  tissues  (A).  Representative  images  of  A549  human  lung 
cancer cells incubated 3 h with LHRH-NLC-DOX-siRNA: (B) visible light; (C) fluorescence 
images  of  nuclei  stained  with  DAPI;  (D)  and  (E)  cellular  localization  of  DOX  (red 
fluorescence) and fluorescently labeled siRNA (green fluorescence), respectively.  ACCEPTED MANUSCRIPT
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Intracellular delivery of anticancer drug and siRNA 
In order to study the penetration of NLC in lung tissues after inhalation, lipids were labeled 
by  osmium  tetroxide  and  visualized  in  slices  of  lung  tissues  by  transmission  electron 
microscopy (Fig. 5A). These data clearly showed that NLC did penetrated lung cells after 
inhalation and accumulated in the cytoplasm. To evaluate the penetration of NLCS into 
cancer cells and the intracellular localization of delivered siRNA  and DOX (intrinsic red 
fluorescence),  LHRH-DOX-NLC  was  complexed  with  FAM-labeled  siRNA  (green 
fluorescence) and then incubated with A549 human lung cancer cells for 3 h. This study 
demonstrated that the developed NLCS successfully delivered chemotherapeutic drug and 
siRNA  into  human  A549  lung  cancer  cells  (Fig.  5B-E).  The  analysis  of  intracellular 
localization by fluorescence microscopy showed that siRNA was predominantly localized in 
the cytoplasm (Fig. 5E), while DOX was evenly distributed in all cellular compartments: 
cytoplasm and nuclei (Fig. 5D).  
Suppression of targeted genes by siRNA 
The  ability  of  siRNA  molecules  delivered  by  NLC  to  silence  the  targeted  mRNA  was 
investigated using RT-PCR. In these experiments, the expression of targeted BCL2 and 
MRP1  genes  was  evaluated  in  mRNA  isolated  from  A549  human  lung  cancer  cells 
incubated with LHRH-TAX-NLC and LHRH-TAX-NLC-siRNA (BCL2 and MRP1) for 24 h. 
Data obtained showed that treatment of lung cancer cells with LHRH-TAX-NLC significantly 
(P < 0.05) increased the expression of both MRP1 and BCL2 mRNA responsible for pump 
and  nonpump  cellular  drug  resistances,  respectively  (Fig.  6A  and  B,  band  and  bar  2). 
Remarkably, siRNA molecules concurrently delivered with TAX by NLC targeted to cancer 
cells by LHRH led to the significant (P < 0.05) decrease in the expression of the BCL2 and 
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Figure 6. Expression of MRP1 (A), BCL2 (B) and  2-m (C and D, internal standard) genes. 
Representative images of RT-PCR products and densitometric analysis of bands in A549 lung 
cancer cells incubated with the following formulations: (1) Control (medium); (2) LHRH-NLC-
TAX; and (3) LHRH-NLC-TAX-siRNAs (MRP1 and BCL2). Gene expression in control was set 
to 100%. Means ± SD are shown. *P < 0.05 when compared with control.  
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MRP1 genes when compared with control cells and cells incubated with free TAX (Fig. 6A 
and B, band and bar 3). Consequently, siRNA delivered by the proposed NLC preserved its 
ability to suppress targeted mRNA. 
Validation of orthotopic model of lung cancer  
The  development  of  orthotopic  mouse  model  of  human  lung  cancer  was  confirmed  by 
several  independent  imaging  techniques  including  optical  imaging  of  lung  cancer  cells 
transfected with luciferase and tumors, MRI, CT and ultrasound imaging systems. Optical 
imaging (Fig. 7A) clearly confirmed the growth of lung cancer in one or, most often, both 
lungs. In addition to imaging of entire animal, lungs, liver, kidneys, heart and brain were 
excised and imaged by the same optical imaging system (Fig. 7E). Images of these organs 
show growth of tumor cells in the lungs. Moreover, approximately in 5% of animals, cancer 
cells were detected in the heart and brain demonstrating the development of metastases. 
MRI  (Fig.  7B-D),  CT  (Fig.  7F-G)  and  ultrasound  (Fig.  7H)  images  confirmed  the 
development of lung tumor.  
Body distribution and accumulation of NLC in the lungs  
 
Figure 7. Evaluation of orthotopic lung cancer model by imaging. (A) Bioluminescence optical 
imaging  of  control  mouse  and  mice  with  lung  tumors  of  different  size.  (B-D)  Magnetic 
resonance imaging of control mouse (B) and mice with lung tumors of different size (C, D). 
Lung tumor (blue) and healthy lung tissues (red) are shown (D). (E) Optical imaging of excised 
organs. (F-G) Computed tomography images of control mouse (F) and mouse with lung tumors 
(G). (H) Visualization of lung tumor by ultrasound imaging system.  
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A Collision nebulizer connected to four-port, nose-only exposure chambers was used for 
inhalation delivery of the developed NLCS labeled Cy5.5 into nude mice with lung cancer. 
Organ distribution of non-targeted NLCS was studied using the IVIS imaging system 24 h 
after a single inhalation or i.v. administration (Fig.8). It was found that inhalation delivery 
substantially enhanced lung exposure to non-targeted NLCS and limited the accumulation 
of the same system in other organs when compared with i.v. administration (Fig. 8A). Thus, 
the  total  amount  of  non-targeted  NLC-TAX-siRNA  retained  in  the  lungs  after  inhalation 
(83%)  was  more  than  3.5  times  higher  when  compared  with  i.v.  injection  of  the  same 
nanoparticles  (23%)  (Fig.  8A).  Targeting  of  nanoparticles  by  LHRH  peptide  does  not 
influence  significantly  on  the  distribution  of  nanoparticles  within  organs  without  tumor. 
However, more detailed analysis showed that in contrast to non-targeted NLCS that was 
distributed uniformly through the lungs after the inhalation, inhaled LHRH-targeted NLCS 
predominately accumulated in the lung tumor avoiding healthy lung tissues (Fig. 8B). The 
data obtained by the IVIS imaging system were confirmed by the fluorescence microscope 
analysis of labeled (red fluorescence) NLC (Fig. 8C). These data demonstrated that NLC 
targeted  specifically  to  cancer  cells  accumulated  predominately  in  the  areas  of  lungs 
contained tumor cells, keeping non-tumorous lung tissues intact.  
Antitumor activity 
The results of the measurement of tumor volume using imaging during the treatment of 
lung cancer with developed NLCS and corresponding controls are presented in Fig. 9. It 
was found that in untreated animals, lung tumor progressively grew reaching 117.1 ± 18.7 
mm
3 (curve 1 in Fig.9) at the end of the experiments (day 24 after the beginning of the 
treatment in other experimental groups). Inhalation treatment (8 times within 4 weeks) of 
mice with lung cancer by LHRH-NLC alone that did not contain an anticancer drug (curve 2 
in Fig. 9) did not change significantly the progression of lung tumor leading to the increase 
of its volume up to 113.6 ± 1.5 mm
3 (P > 0.05 when compared with untreated control). 
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Figure  8.  Accumulation  of  NLC  in  the  lungs  and  other  organs.  (A)  Organ  distribution  of 
fluorescently labeled (Cy5.5) NLC in mice after i.v. (left) and inhalation (right) administration. 
(B) Distribution of fluorescently labeled (Cy5.5) non-targeted and LHRH-tumor targeted NLC in 
mouse  lungs  bearing  human  lung  cancer.  (C)  Distribution  of  fluorescently  labeled  (Cy5.5) 
LHRH-tumor - targeted (NLC-LHRH) in mouse lungs bearing human lung tumor cells (tumor 
and non-tumor tissues; bright field and fluorescence microscope images; red color represents 
distribution of NLC-LHRH in tumor and non-tumor lung tissues). 
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Treatment  with  free  unbound  TAX 
partially slowed down the growth of the 
tumor (curve  3  in  Fig.  9).  In  this case 
the  tumor  volume  at  the  end  of  the 
experiment  was  82.2  ±  9.8  mm
3  (P  < 
0.05  when  compared  with  untreated 
control). The conjugation of TAX to the 
NLC  targeted  to  tumor  cells  by  LHRH 
and  local  delivery  by  inhalation 
significantly enhanced antitumor activity 
of  TAX  (curve  4  in  Fig.  9).  After 
treatment  with  LHRH-NLC-TAX  the 
tumor size decreased at the end of the 
experiment down to 20.8 ± 4.4 mm
3 (P 
<  0.05  when  compare  both  with  initial 
tumor  volume  at  day  0  and  untreated 
animals  at  day  24).  Finally,  the 
suppression  of  both  pump  and 
nonpump  cellular  drug  resistance  in 
lung cancer cells led to almost complete 
regression of the tumor (curve 5 in Fig. 
9).  In  fact,  the  tumor  size  in  animals 
treated  with  LHRH-NLC-TAX-siRNAs 
(MRP1 and BCL2) shrank down to 2.6 ± 
3.0 mm
3 (P < 0.05 when compared with 
other  treatments  and  initial  tumor 
volume). It should also be stressed that in 50% of animals the level of bioluminescence of 
cancer cells in the lungs was below the detectable limit of the optical systems used. These 
findings indicate almost complete disappearance of lung tumor in experimental animals. In 
these cases other imaging techniques also were not able to detect lung tumor after the 
treatment with LHRH-NLC-TAX-siRNAs. 
Discussion 
The  ultimate  goal of  the  present  study  was  the  development of a  multifunctional tumor 
targeted  system  capable  of  delivering  an  anticancer  drug  simultaneously  with  siRNA 
specifically to the lung tumor. We used nanostructured lipid carriers as a vehicle to achieve 
this goal. In this system, NLC was used as carriers, an anticancer drug served as cell death 
inducer and siRNA as a suppressor of cellular drug resistance in cancer cells. Previously, 
we identified MRP1 and BCL2 mRNA as major targets to suppress pump and nonpump 
cellular resistance in lung cancer cells, respectively [11, 17, 22, 34]. Consequently, in order 
to simultaneously suppress both types of cellular resistance in lung cancer cells, two types 
of siRNA molecules were used. The first type of siRNA was targeted to MRP1 mRNA and 
was used to suppress the main drug efflux transporter in lung cancer cells. The second 
type was targeted to BCL2 mRNA and was used to suppress cellular antiapoptotic defense 
± the main component of nonpump resistance. In order to deliver active components of the 
NLCS  specifically  to  the  lungs,  local  delivery  by  inhalation  of  NLCS  was  used.  The 
inhalation  delivery  led  to  the  preferential  accumulation  of  NLCS  in  the  lungs  when 
 
Figure  9.  Changes  in  lung  tumor  volume  after 
beginning  of  treatment.  Mice  were  treated  on 
days  0,  3,  7,  11,  14,  17,  21,  and  24.  1  ± 
Untreated mice; 2 ± LHRH-NLC (inhalation); 3 ± 
TAX (i.v.); 4 ± LHRH-NLC-TAX (inhalation); 5 ± 
LHRH-NLC-TAX-siRNAs  targeted  to  MRP1  and  
BCL2  mRNAs  (inhalation).  Means  ±  SD  are 
shown.  
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compared with accumulation in other organs. In contrast, intravenous injection of the same 
nanosystem led to the predominant accumulation of NLCS in the liver, kidney and spleen, 
while much less amount of nanoparticles was found in the lungs. Such passive targeting by 
the local delivery to the lung substantially limited possible adverse side effects on healthy 
organs. To further target NLCS specifically to lung cancer cells,  we utilized a synthetic 
analog of LHRH peptide as a targeting moiety in NLCS. Previously, we found that LHRH 
receptors are overexpressed in different cancer cells (including lung cancer cells) and are 
not expressed to a detectable level in healthy visceral organs [18-20, 27, 28, 32, 39, 41, 
42]. Therefore, the present experimental treatment approach involves a dual targeting of 
NLCS. On the one hand, inhalation provides for a local delivery of therapeutics directly to 
the lungs (passive targeting). On the other hand, targeting of the NLCS specifically to lung 
cancer  cells  by  LHRH  (active  targeting)  enforces  a  preferential  accumulation  of  active 
components  in  lung  cancer  cells  leaving  healthy  lung  cells  intact.  Data  obtained  in  the 
present investigation support the proposed dual targeting approach. We found that LHRH-
targeted  NLCS  after  inhalation  accumulated  predominately  in  the  lungs  and  more 
specifically in the lung cancer cells. Hence, the use of LHRH as a cancer-targeting moiety 
adds specificity to the NLCS and enhances tumor targeted drug delivery by combining a 
passive lung targeting (local inhalation delivery) with powerful active targeting specifically to 
cancer cells (LHRH peptide). 
To  effectively  perform  their  action,  all  active  components  should  be  delivered  into  the 
cancer cell,  distributed  inside  the  cell  in  right  compartments and  preserve  their  specific 
activity.  Data  obtained  in  the  present  study  clearly  show that  the  proposed  NLC-based 
tumor targeted delivery system penetrates cancer cells and delivers its payload. Different 
anticancer  drugs  can  have  different  mechanisms  of  action  and  require  cytoplasmic  or 
nuclear delivery in order to induce cell death. For example, the major mechanism of DOX 
involves DNA damage through topoisomerase II inhibition and DNA intercalation [43, 44]. 
Consequently, it should be delivered into the nucleus in order to effectively kill cancer cells. 
In  contrast,  siRNA  acts  in  the  cytoplasm  via  the  RNA  interference  [45].  Therefore,  the 
primary localization of delivered siRNA inside the cells should be in the cytoplasm. We 
found that the proposed targeted NLCS is capable of transporting an anticancer drug both 
in the cytoplasm and cellular nuclei, while delivered siRNA was predominately localized in 
the  cytoplasm.  We  found  that  TAX  delivered  by  targeted  NLCS  inside  cancer  cells 
efficiently induced cell death in lung cancer cells and slowed down the progression of lung 
tumor or even completely eliminated it. Similarly, both types of siRNA (targeted to MRP1 
and  BCL2  mRNAs)  after  the  release  from  the  NLCS  were  capable  to  silence  targeted 
genes. Consequently, the proposed NLCS provided for an effective intracellular delivery of 
anticancer drugs and siRNA in the required compartments of cancer cells and delivered 
components were capable to perform their major functions ± induction of cell death and 
silencing of targeted genes specifically in lung tumor cells. 
Our  previous  investigations  showed  that  for  effective  killing  of  cancer  cells,  cell  death 
induction  should  be  accompanied  with  the  suppression  of  cellular  drug  resistance  and 
identified the major mechanisms of such resistance. We termed two main components of 
drug  resistance  as  "pump"  and  "nonpump"  resistance  [10,  11,  17].  So-called  pump 
resistance is mainly caused by the active efflux of anticancer drugs by drug efflux pumps. 
The second major component of cellular drug resistance includes mechanisms that prevent 
the progression of cellular damage caused by an anticancer drug into cell death, but do not ACCEPTED MANUSCRIPT
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involve drug efflux pumps. It may include drug detoxification mechanisms, interruption or 
inhibition  of  cell  death  signal,  mechanisms  of  repairing  of  cellular  damage  on  different 
levels,  antioxidant  defense,  etc.  However,  the  most  powerful  mechanism  of  nonpump 
cellular  resistance  in  many  cancer  cells  is  antiapoptotic  defense.    Our  previous 
investigations identified MRP1 and BCL2 proteins as major players in pump and nonpump 
resistance, respectively, in lung cancer cells [11, 17, 28, 34]. Consequently, two types of 
siRNA targeted to MRP1 and BCL2 mRNA were included into the proposed NLCS for local 
inhalation delivery to the lungs. Data obtained showed that suppression of both pump and 
nonpump  resistance  substantially  enhanced  anticancer  activity  of  the  chemotherapeutic 
drug and led to the effective cell death induction, killing of cancer cells and regression in 
the  growth  of  lung  tumors  or  almost  complete  tumor  disappearance.  Therefore,  the 
proposed NLCS effectively performed its multifunctional task providing simultaneous cell 
death induction and suppression of drug resistance in lung cancer cells. 
Conclusions 
The proposed nanocarrier-based targeted delivery system demonstrated high efficiency in 
delivering of anticancer drugs and two types of siRNA specifically to lung tumor cells via 
inhalation. It accumulated predominately in the lungs and more specifically in lung cancer 
cells leaving healthy organs and non-tumorous lung cells intact. The system also showed 
enhanced antitumor efficiency when compared with free drug or similar system delivered 
intravenously.  
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Figure legends 
Figure 1. A schematic representation of Nanostructured Lipid Carrier (NLC)-based drug 
delivery  system  for  pulmonary  co-delivery  of  an  anticancer  drug,    siRNA  and  targeting 
peptide. 
Figure 2. Characterization of LHRH-targeted paclitaxel (TAX)-loaded Nanostructured Lipid 
Carriers  (LHRH-NLC-TAX-siRNA).  (A)  Size  distribution  of  LHRH-NLC-TAX-siRNA 
measured  by  dynamic  light  scattering  before  and  after  nebulization.  (B)  Atomic  Force 
Microscope image of LHRH-NLC-TAX-siRNA.  
Figure  3.  Complexation  of  siRNA  with  NLC.  (A)  A  representative  agarose  gel 
electrophoresis image illustrating siRNA complexation efficiency by LHRH-NLC-TAX at the 
following w/w ratio (weight NLC/weight siRNA): (1) 0:1 (naked siRNA, control); (2) 10:1; (3) 
50:1;  (4) 100:1; and  (5) 117:1.  Complexation  of  siRNA  prevented  staining  of  siRNA  by ACCEPTED MANUSCRIPT
ACCEPTED MANUSCRIPT
19 
 
ethidium  bromide  and  led  to  the  disappearance  of  the  siRNA  band.  Therefore,  the 
fluorescent intensity of the siRNA band on the gel (well 5) disappeared when siRNA was 
complexed with NLC at w/w ratio = 117:1. (B) siRNA complexation efficiency of LHRH-
NLC-TAX evaluated by the ethidium bromide dye displacement assay. The arrow on the 
curve highlights the w/w ratio corresponding to the apparent end of siRNA complexation 
with NLC. Means ± SD are shown.  
Figure 4. Viability of multidrug-resistant H69AR human lung cancer cells incubated for 48 
hours with the indicated formulations. A, cytotoxicity of formulations that do not contain 
DTAX; B, cytotoxicity of formulations that contain TAX. Means ± SD are shown. *P < 0.05 
when compared with control. 
Figure  5.  Accumulation  of  NLC  in  the  lung  tissues  after the  inhalation delivery  (A) and 
intracellular localization of the drug and siRNA released from NLC (B-E). Representative 
transmission  electron  microscopy  image  of  NLC  labeled  with  osmium  tetroxide  in  lung 
tissues (A). Representative images of A549 human lung cancer cells incubated 3 h with 
LHRH-NLC-DOX-siRNA: (B) visible light; (C) fluorescence images of nuclei stained with 
DAPI; (D) and (E) cellular localization of DOX (red fluorescence) and fluorescently labeled 
siRNA (green fluorescence), respectively.  
Figure 6. Expression of MRP1 (A), BCL2 (B) and  2-m (C and D, internal standard) genes. 
Representative images of RT-PCR products and densitometric analysis of bands in A549 
lung  cancer  cells  incubated  with  the  following  formulations:  (1)  Control  (medium);  (2) 
LHRH-NLC-TAX; and (3) LHRH-NLC-TAX-siRNAs (MRP1 and BCL2). Gene expression in 
control was set to 100%. Means ± SD are shown. *P < 0.05 when compared with control.  
Fig.7. Evaluation of orthotopic lung cancer model by imaging. (A) Bioluminescence optical 
imaging  of  control  mouse  and  mice  with  lung  tumors  of  different  size.  (B-D)  Magnetic 
resonance imaging of control mouse (B) and mice with lung tumors of different size (C, D). 
Lung tumor (blue) and healthy lung tissues (red) are shown (D). (E) Optical imaging of 
excised organs. (F-G) Computed tomography images of control mouse (F) and mouse with 
lung tumors (G). (H) Visualization of lung tumor by ultrasound imaging system.  
Figure 8. Accumulation of NLC in the lungs and other organs. (A) Organ distribution of 
fluorescently  labeled  (Cy5.5)  NLC  in  mice  after  i.v.  (left)  and  inhalation  (right) 
administration.  (B) Distribution of fluorescently  labeled  (Cy5.5) non-targeted  and  LHRH-
tumor  targeted  NLC  in  mouse  lungs  bearing  human  lung  cancer.  (C)  Distribution  of 
fluorescently labeled (Cy5.5) LHRH-tumor - targeted (NLC-LHRH) in mouse lungs bearing 
human  lung  tumor  cells  (tumor  and  non-tumor  tissues;  bright  field  and  fluorescence 
microscope images; red color represents distribution of NLC-LHRH in tumor and non-tumor 
lung tissues). 
Fig. 9. Changes in lung tumor volume after beginning of treatment. Mice were treated on 
days 0, 3, 7, 11, 14, 17, 21, and 24. 1 ± Untreated mice; 2 ± LHRH-NLC (inhalation); 3 ± 
TAX (i.v.); 4 ± LHRH-NLC-TAX (inhalation); 5 ± LHRH-NLC-TAX-siRNAs targeted to MRP1 
and BCL2 mRNAs (inhalation). Means ± SD are shown.  
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